Obinutuzumab (GA101) is highly effective against chronic lymphocytic leukemia cells in ex vivo B-cell depletion irrespective of high-risk prognostic markers

Blood Cancer J. 2015 Nov 13;5(11):e367. doi: 10.1038/bcj.2015.93.

Authors

L Ysebaert^{1

2}, E Laprévotte¹, C Klein³, A Quillet-Mary¹

Affiliations

¹ CRCT, UMR1037 Inserm-University, Toulouse III Paul Sabatier-ERL5294 CNRS, Toulouse, France.
² Department of Haematology, Institut Universitaire du Cancer de Toulouse, Toulouse, France.
³ Roche Innovation Center Zurich, Roche Pharma Research and Early Development, Schlieren, Switzerland.

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Antibodies, Monoclonal, Humanized / therapeutic use*
Antineoplastic Agents / therapeutic use*
B-Lymphocytes / pathology*
Biomarkers
Humans
Leukemia, Lymphocytic, Chronic, B-Cell / drug therapy*
Leukemia, Lymphocytic, Chronic, B-Cell / pathology
Rituximab / therapeutic use*

Substances

Antibodies, Monoclonal, Humanized
Antineoplastic Agents
Biomarkers
Rituximab
obinutuzumab